Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma

To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC). In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2007-08, Vol.25 (24), p.3766-3773
Hauptverfasser:	ELSER, Christine, SIU, Lillian L, WILKIE, Dean, PETRENCIUC, Oana, CHEN, Eric X, WINQUIST, Eric, AGULNIK, Mark, POND, Gregory R, CHIN, Soo F, FRANCIS, Peggy, CHEIKEN, Robin, ELTING, James, MCNABOLA, Angela
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Benzenesulfonates - therapeutic use Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - secondary Disease Progression Disease-Free Survival Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - mortality Head and Neck Neoplasms - pathology Humans Male Medical sciences Middle Aged Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - pathology Neoplasm Recurrence, Local Niacinamide - analogs & derivatives Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Phenylurea Compounds Protein Kinase Inhibitors - therapeutic use Pyridines - therapeutic use raf Kinases - antagonists & inhibitors Survival Rate Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC). In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patients had
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2006.10.2871